Stereotactic Radiosurgery in the Treatment of Essential Tremor
Launched by MARIA SKLODOWSKA-CURIE NATIONAL RESEARCH INSTITUTE OF ONCOLOGY · Feb 6, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called stereotactic radiosurgery for people with essential tremor, a condition that causes uncontrollable shaking, usually in the hands. The goal is to see if this treatment can help those who have not found relief from medications and are not eligible for other surgical options. The trial is currently looking for participants who are 50 years or older, have been diagnosed with essential tremor for at least five years, and have not had success with available treatments.
If someone decides to join the study, they will receive the stereotactic radiosurgery treatment and will be monitored to see how effective it is in reducing their tremors. It’s important for potential participants to know that they need to provide consent to take part in the trial and that certain health conditions, like severe illness or previous brain treatments, may prevent them from joining. This study is an opportunity for individuals who struggle with essential tremor to potentially find a new way to manage their symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Essential tremor diagnosed, Parkinson's disease and other causes of tremor excluded.
- • Insufficient tremor control despite the use of available pharmacotherapy methods.
- • Disqualification from the Deeply Brain Stimualtion procedure/lack of consent to perform it on the side qualified for Stereotactic Radiosurgery
- • Consent to participate in a clinical trial.
- Exclusion Criteria:
- • Age under 50
- • Pregnancy
- • Duration of the disease less than 5 years
- • Dementia, psychosis or other condition that prevents giving informed consent to participate in the study
- • Poor general condition, serious comorbidities
- • Structural changes in the basal ganglia or major atrophic changes
- • Previous radiotherapy to the brain covering the potential treatment area
- • Medical contraindications to magnetic resonance imaging
About Maria Sklodowska Curie National Research Institute Of Oncology
The Maria Skłodowska-Curie National Research Institute of Oncology is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and translational research. Located in Poland, the institute focuses on a multidisciplinary approach, integrating cutting-edge scientific research with clinical applications to enhance patient outcomes. With a commitment to excellence in oncology, the institute collaborates with national and international partners to conduct rigorous studies that contribute to the global understanding of cancer biology and therapy. Its mission is to provide valuable insights that drive the development of new therapeutic strategies and improve the quality of care for cancer patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gliwice, , Poland
Patients applied
Trial Officials
Aleksandra Napieralska
Principal Investigator
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported